CSL Limited (ASX:CSL) gains over 16% in six months, here’s why

2 min read | July 25, 2022 06:43 PM AEST | By Ritwika

Google News:

CSL Limited (ASX:CSL) gains over 16% in six months, here’s why — Image source: Image source: © Timonschneider | Megapixl.com

Recent News

ASX Rare Earth Stocks Surge as Global Supply Battle Intensifies

ASX Healthcare Outlook on ASX 100 Amid GLP-1 Debate

Healthcare Reset: ASX 100 Giants Under the Spotlight

Why Did ASX 200 Healthcare Face a Brutal Reset?

Make Kalkine Media
My Trusted Source

Highlights:

Healthcare giant CSL Limited has been making headlines lately because of several reasons.

The pharma company is all set to buy Vifor for US$11.7 billion.

CSL, along with Queensland University, is working on a COVID-19 vaccine development project.

The company also makes COVID-19 shots for AstraZeneca.

Today, shares of the company ended 0.841% lower. The benchmark S&P/ASX 200 Health Care sector closed in red too.

Leading Australian healthcare firm CSL Limited (ASX:CSL) shares closed tad down, declining 0.841% at AU$291.00 on the ASX today. It should be noted that the share price of CSL has gained 16.67% in last six months and 6.59% in last one month. Though the stock has declined 1.69% on Y-T-D basis.

What is affecting CSL shares?

The S&P/ASX 200 index (INDEXASX:XJO) closed in the red territory today, along with seven other sectors under its auspices. The S&P/ASX 200 Health Care sector (INDEXASX:XHJ) was one of the worst performing sectors on the ASX today. It ended 1.023% lower to 42553.6 points.

An important factor impacting CSL's share price altogether these days is the Vifor acquisition. As per the latest update, the takeover is getting a bit delayed due to the lack of regulatory approvals.

Vifor Pharma is a Switzerland-based developer, manufacturer and marketer of pharmaceutical products that are used in the treatment of kidney and iron deficiency diseases. As a result, CSL expects a boost in its business post this acquisition.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.